0001127602-22-014711.txt : 20220517 0001127602-22-014711.hdr.sgml : 20220517 20220517132056 ACCESSION NUMBER: 0001127602-22-014711 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220516 FILED AS OF DATE: 20220517 DATE AS OF CHANGE: 20220517 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Farrell Michael J. CENTRAL INDEX KEY: 0001485164 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15317 FILM NUMBER: 22933473 MAIL ADDRESS: STREET 1: C/O REMED INC STREET 2: 9001 SPECTRUM CTR. BLVD. CITY: SAN DIEGO, STATE: CA ZIP: 92123 FORMER NAME: FORMER CONFORMED NAME: Farrell Michael DATE OF NAME CHANGE: 20100224 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RESMED INC CENTRAL INDEX KEY: 0000943819 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980152841 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 9001 SPECTRUM CENTER BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92123 BUSINESS PHONE: 8587462400 MAIL ADDRESS: STREET 1: 9001 SPECTRUM CENTER BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92123 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2022-05-16 0000943819 RESMED INC RMD 0001485164 Farrell Michael J. RESMED INC. 9001 SPECTRUM CENTER BLVD SAN DIEGO CA 92123 1 Chief Executive Officer ResMed Common Stock 2022-05-16 4 M 0 5675 57.76 A 410935 D ResMed Common Stock 2022-05-16 4 S 0 5675 196.607 D 405260 D ResMed Common Stock 3880 I Lisette and Michael Farrell Foundation ResMed Common Stock 5090 I Lisette and Michael Farrell Family Trust ResMed Common Stock Options 57.76 2022-05-16 4 M 0 5675 0 D 2017-11-11 2023-11-16 ResMed Common Stock 5675 105615 D The transaction was conducted under a Rule 10b5-1 plan. This transaction was executed in multiple trades at prices ranging from $195.10 to $198.04. The price reported above reflects the weighted average sale price. Includes 30.8872 shares of ResMed stock purchased on April 29, 2022, through the ResMed Employee Stock Purchase Plan. Represents date options first became exercisable. Options vest 1/3 per year. Michael J. Farrell, Chief Executive Officer 2022-05-17